% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bunse:305088,
      author       = {L. Bunse$^*$ and T. Bunse$^*$ and M. Kilian and F. J.
                      Quintana and M. Platten$^*$},
      title        = {{T}he immunology of brain tumors.},
      journal      = {Science immunology},
      volume       = {10},
      number       = {112},
      issn         = {2470-9468},
      address      = {Washington, DC},
      publisher    = {AAAS},
      reportid     = {DKFZ-2025-02040},
      pages        = {eads0449},
      year         = {2025},
      note         = {#EA:D170#LA:D170#},
      abstract     = {Brain tumors represent a unique challenge for cancer
                      immunotherapies because of their location in an immune
                      privileged site. However, the brain tumor immune
                      microenvironment is dictated more by tumor type than the
                      location within the brain per se. This feature is reflected
                      by the higher immunogenicity and response to immunotherapies
                      of metastatic brain tumors compared with primary brain
                      tumors. Immunotherapies for brain tumors aim at inducing and
                      boosting tumor T cell responses using vaccines, immune
                      checkpoint inhibitors, or adoptive T cell therapies. A
                      fundamental challenge in the field is how such brain
                      tumor-targeting T cells gain access to brain tumors and
                      maintain their function despite a hostile immunosuppressive
                      microenvironment. Here, we review current knowledge of the
                      cellular and molecular determinants of the antigenicity of
                      brain tumors and the immunosuppressive brain tumor
                      microenvironment. Expanding and exploiting this knowledge
                      will provide the key for effective combinatorial therapies.},
      subtyp        = {Review Article},
      keywords     = {Humans / Brain Neoplasms: immunology / Brain Neoplasms:
                      therapy / Tumor Microenvironment: immunology / Animals /
                      Immunotherapy: methods / T-Lymphocytes: immunology / Cancer
                      Vaccines: immunology / Cancer Vaccines (NLM Chemicals)},
      cin          = {D170 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)D170-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41042911},
      doi          = {10.1126/sciimmunol.ads0449},
      url          = {https://inrepo02.dkfz.de/record/305088},
}